Correcting the ASCO position on phase I clinical trials in cancer
Correcting the ASCO position on phase I clinical trials in cancer
Related Articles
AI accurately identifies targetable alterations in lung cancer histological images
Nature Reviews Clinical Oncology – DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples…
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Nature Reviews Clinical Oncology – Accumulating evidence indicates that NUT carcinoma, a highly aggressive malignancy driven by NUTM1 fusions, is a rare form of squamous…
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and…
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC
Nature Reviews Clinical Oncology – Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC
Thermal ablation is safer than resection of colorectal liver lesions
Nature Reviews Clinical Oncology – Thermal ablation is safer than resection of colorectal liver lesions
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and…
Early promising results with addition of an ICI and an anti-angiogenic to TACE
Nature Reviews Clinical Oncology – Early promising results with addition of an ICI and an anti-angiogenic to TACE
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and…
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients…
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients…